Roundtable Discussion: Untangling the Regulatory Landscape Surrounding Combination Therapies to Accelerate More Innovative Treatments Towards the Patients in Need
- How to overcome the regulatory hurdles associated with combining two unapproved drugs?
- Uncovering preclinical data and safety assessments required for combining a RAS inhibitor with another approved or unapproved drug
- How do regulatory agencies assess and manage multi-drug interactions in clinical trials?